Molecular determinants for ligand binding at Nav1.4 and Nav1.7 channels: Experimental affinity results analyzed by molecular modeling

Here, we focused on exploring the selectivity mechanism against Nav1.7 over Nav1.4 due to different binding modes of two selected inhibitors. By the superposition of Nav1.7 and Nav1.4 proteins, we selected the most homologous chain of Nav1.7 with Nav1.4, defining the active site of Nav1.4-VSD4 based on the aryl sulfonamide binding site of Nav1.7-VSD4. Comparison of the conformations exhibited by Tyr1386 (Nav1.4) and Tyr1537 (Nav1.7) suggested that the steric hindrance caused by Tyr1386 owned primary influence on inhibition selectivity, which was further verified through molecular docking and MD simulation of two representative inhibitors. Our finding would be helpful for discovery of selective Nav1.7 inhibitors over Nav1.4.

[1]  Ying Wang,et al.  In silico exploration of aryl sulfonamide analogs as voltage-gated sodium channel 1.7 inhibitors by using 3D-QSAR, molecular docking study, and molecular dynamics simulations , 2018, Comput. Biol. Chem..

[2]  Roman Shimanovich,et al.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. , 2017, Journal of medicinal chemistry.

[3]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[4]  Jun Li,et al.  Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist , 2015, Science.

[5]  Sharan K Bagal,et al.  Recent progress in sodium channel modulators for pain. , 2014, Bioorganic & medicinal chemistry letters.

[6]  Yongbo Song,et al.  In silico insight into voltage-gated sodium channel 1.7 inhibition for anti-pain drug discovery. , 2018, Journal of molecular graphics & modelling.

[7]  Dong Liu,et al.  Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. , 2016, Journal of medicinal chemistry.

[8]  Jinghai Zhang,et al.  Investigation of the selectivity of one type of small-molecule inhibitor for three Nav channel isoforms based on the method of computer simulation , 2019, Journal of biomolecular structure & dynamics.

[9]  Mirko Rivara,et al.  Novel sodium channel antagonists in the treatment of neuropathic pain , 2016, Expert opinion on investigational drugs.

[10]  Wonseok Chang,et al.  Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel , 2017, Neuroscience Bulletin.

[11]  Yasushi Tojo,et al.  Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics-Based Ligand Charges and a Hybrid Water Model , 2009, J. Chem. Inf. Model..

[12]  Qiang Zhou,et al.  Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1 , 2018 .

[13]  Michael A Rossi,et al.  Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model. , 2017, Bioorganic & medicinal chemistry letters.

[14]  C. Cohen,et al.  Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. , 2014, Pharmaceutical patent analyst.

[15]  B. Norman,et al.  Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. , 2017, Journal of medicinal chemistry.

[16]  J. Wood,et al.  Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief , 2016, Expert opinion on therapeutic targets.

[17]  M. Palcic,et al.  Conserved residues Arg188 and Asp302 are critical for active site organization and catalysis in human ABO(H) blood group A and B glycosyltransferases. , 2018 .

[18]  N. Meanwell,et al.  Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain. , 2018, Journal of medicinal chemistry.

[19]  Jianping Wu,et al.  Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution , 2017, Science.

[20]  Jingyu Zhu,et al.  Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations , 2017, Chemical biology & drug design.

[21]  Benjamin D. Sellers,et al.  Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (NaV) 1.7 with Potent Analgesic Activity. , 2018, Journal of medicinal chemistry.

[22]  J. Kaplan,et al.  The Neuropeptides FLP-2 and PDF-1 Act in Concert To Arouse Caenorhabditis elegans Locomotion , 2016, Genetics.

[23]  L. Ye,et al.  Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia. , 2017, Bioorganic & medicinal chemistry letters.

[24]  L. Poppe,et al.  Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. , 2015, Journal of Medicinal Chemistry.

[25]  P. A. Bradley,et al.  Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7. , 2017, Journal of medicinal chemistry.

[26]  Dong Liu,et al.  Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7 , 2017, The Journal of Pharmacology and Experimental Therapeutics.